Evommune (NYSE:EVMN) Research Coverage Started at Leerink Partners

by · The Cerbat Gem

Leerink Partners began coverage on shares of Evommune (NYSE:EVMN – Free Report) in a research report released on Monday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $42.00 price objective on the stock.

EVMN has been the topic of several other reports. Evercore ISI initiated coverage on shares of Evommune in a research report on Monday. They set an “outperform” rating and a $40.00 target price on the stock. Cantor Fitzgerald assumed coverage on Evommune in a research report on Monday. They set an “overweight” rating on the stock. William Blair started coverage on Evommune in a research note on Monday. They issued an “outperform” rating for the company. Wall Street Zen raised Evommune to a “hold” rating in a research report on Thursday, November 20th. Finally, Morgan Stanley started coverage on Evommune in a research report on Monday. They issued an “overweight” rating and a $36.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $39.33.

Check Out Our Latest Analysis on Evommune

Evommune Stock Performance

Shares of EVMN opened at $21.22 on Monday. Evommune has a fifty-two week low of $16.70 and a fifty-two week high of $24.03.

About Evommune

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.

See Also